Glenmark Pharma gains as its arm to launch Leucovorin Calcium for Injection USP
Glenmark Pharmaceuticals is currently trading at Rs. 1966.00, up by 13.10 points or 0.67% from its previous closing of Rs. 1952.90 on the BSE.
The scrip opened at Rs. 1953.95 and has touched a high and low of Rs. 1966.00 and Rs. 1946.25 respectively. So far 3204 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 1988.50 and Rs. 1893.00 respectively. The current market cap of the company is Rs. 55115.23 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.38% and 13.97% respectively.
Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is all set to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. Glenmark’s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Leucovorin Calcium for Injection, 350 mg/vial, of Hospira, Inc. Glenmark will begin distribution in December 2025.
According to IQVIA sales data for the 12-month period ending October 2025, the Leucovorin Calcium for Injection, 350 mg/vial market achieved annual sales of around $16.8 million. Glenmark’s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
